Latest Deals
BMS and BioNTech are now contestants in a fast-moving clinical arena that looks to go beyond traditional single-mechanism checkpoint inhibitors. Credit: HJBC / Shutterstock
BMS outlays $11bn to join BioNTech’s development of bispecific cancer drug
Bristol Myers Squibb (BMS) is joining forces with BioNTech in a deal that could surpass $11bn. The deal will see BMS partner with BioNTech on a bispecific antibody candidate, dubbed BNT327, of which the latter company is currently developing. BMS will pay an upfront cost of $1.5bn, as well as $2bn in non-contingent anniversary payments through 2028.
AstraZeneca taps Chinese biotech in $5.2bn chronic disease research deal
AstraZeneca has joined the long list of big pharma companies enlisting the services of Chinese biotechs, signing a deal worth up to $5.2bn with CSPC Pharmaceuticals to research chronic disease drug candidates. Under the deal, AstraZeneca will pay an upfront fee of $110m, along with milestone payments of $1.62bn. CSPC are also in line to receive $3.6bn in sales milestone payments.
BioNTech bolsters mRNA pipeline with $1.25bn CureVac acquisition
BioNTech has agreed to acquire mRNA specialist CureVac for approximately $1.25bn, as the big pharma company amps up its strategy to offer cancer treatments using the modality. According to the deal, each CureVac share will be exchanged for approximately $5.46 in BioNTech American depositary shares (ADS). This gives an aggregate equity value of around $1.25bn for CureVac.
Novo Nordisk signs $812m research deal with Deep Apple for non-GLP-1 drugs
Novo Nordisk is eyeing a cardiometabolic drug market future that is not purely dominated by incretins, after signing a $812m partnership with Deep Apple Therapeutics. The research collaboration and exclusive worldwide license agreement will see Deep Apple tasked with discovering and optimising drug candidates directed at a non-incretin G protein-coupled receptor target.
